ERBB2 and pancreatic ductal adenocarcinoma: Using a bispecific Ab engaging both HER2/neu and γ9 in combination with adoptive transfer of Vγ9Vδ2 T cells in a pancreatic ductal adenocarcinoma xenograft mouse model, a significant reduction in tumor growth was achieved, while the single arm Vγ9Vδ2 T cell therapy was not effective [127].